Floatz logo

Spm 927

Epilepsies, Partial

UCB PharmaPhase 2/3Dormant
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
46/ 100
Competitive Position
95/ 100

Competitive context

25 Active assets in the Epilepsies, Partial cohort.

Asset / SponsorPhaseRating
Eslicarbazepine Acetate
Sumitomo Pharma America, Inc.
Phase 4A
Pregabalin
Yung Shin Pharm. Ind. Co., Ltd.
Phase 4A
Lacosamide
Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Phase 4A
Topamax
Mario Negri Institute for Pharmacological Research
Phase 4A
Oxcarbamezapine
Mario Negri Institute for Pharmacological Research
Phase 4A

View all 50 →

Same molecule, other indications

Spm 927 is also rated in:

postherpetic neuralgiaDormant
B
Indicative ·
57 / 100
View asset →
epilepsyDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →